Long‐term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post‐hoc analysis of <scp>SURPASS</scp> ‐4
Tirzepatide significantly improved glycaemic control and body weight reduction compared to insulin glargine over 104 weeks in participants with type 2 diabetes inadequately controlled on metformin and/or sulfonylurea. The safety profile of tirzepatide was acceptable, with a lower incidence of hypoglycaemia than insulin glargine.
Authors
- Jiawei Xu (ORCID: https://orcid.org/0000-0002-6289-5589)
- Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
- Haixia Guan (ORCID: https://orcid.org/0000-0003-3155-2847)
- Huijuan Yuan (ORCID: https://orcid.org/0000-0001-8151-0595)
- Hongwei Jiang
- Jie Sun (ORCID: https://orcid.org/0009-0006-5321-6827)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Henan Provincial People's Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Guangdong Academy of Medical Sciences (CN)
- Lilly (China) (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1111/dom.70047
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company